We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Advisory Committee Deadlocks on Durect’s Post-Surgical Analgesic
Advisory Committee Deadlocks on Durect’s Post-Surgical Analgesic
The FDA’s Anesthetic and Analgesic Drug Products Advisory Committee split yesterday in a 6-6 vote over Durect’s Posirim (bupivacaine extended-release solution) for post-surgical analgesia.